Rebecca Araujo

DocwireNews

Patients with light-chain (AL) amyloidosis with low disease burden who are eligible for autologous hematopoietic cell transplantation (AHCT) may benefit from receiving bortezomib-based induction therapy, according to a new study.
Induction therapy is a recommended treatment for patients with AL amyloidosis prior to AHCT if the patient has a high disease burden or more than 10% bone marrow plasma cells. The role of induction therapy before AHCT in patients with AL amyloidosis with low disease burden has not been previously studied.
A team of researchers from the Nanjing University School of Medicine in China, enrolled 227 patients with low disease burden AL amyloidosis in a study to examine outcomes associated with bortezomib-based induction therapy prior to AHCT. Of the 227 patients, 124 received bortezomib-based induction, 35 received other chemotherapeutic induction, and 68 did not receive induction. Differences of efficacy and prognosis were assessed between the three groups.
Hematologic overall response rates were 92% for the bortezomib group, 67% for the chemotherapy group, and 75% for the non-induction group, with complete response rates of 50%, 25%, and 20%, respectively. The renal response rates of the bortezomib, chemotherapy, and non-induction groups were 64%, 46%, and 47%, respectively, and cardiac response rates were 74%, 45%, and 40%, respectively.
Median overall survival (OS) was not met at 44 months. The five-year estimated OS of the three groups was 81% for bortezomib, 57% for chemotherapy, and 67% for non-induction. Median progression-free survival (PFS) was 83 months for all patient groups. The five-year estimated PFS rates were 61% for bortezomib, 38% for chemotherapy, and 49% for non-induction.
Upon multivariate analysis, a baseline difference between involved and uninvolved free light chains of more than 50 mg/L was associated with worse survival. Overall, induction with bortezomib was associated with better survival.
This <a href="https://pubmed.ncbi.nlm.nih.gov/33084412/">study</a> was published in Amyloid.

Patients with light-chain (AL) amyloidosis with low disease burden who are eligible for autologous hematopoietic cell transplantation (AHCT) may benefit from receiving bortezomib-based induction therapy, according to a new study.Induction therapy is a recommended treatment for patients with AL amyloidosis prior to AHCT if the patient has a high disease burden or more than 10% bone marrow plasma cells. The role of induction therapy before AHCT in patients with AL amyloidosis with low disease burden has not been previously studied.A team of researchers from the Nanjing University School of Medicine in China, enrolled 227 patients with low disease burden AL amyloidosis in a study to examine outcomes associated with bortezomib-based induction therapy prior to AHCT. Of the 227 patients, 124 received bortezomib-based induction, 35 received other chemotherapeutic induction, and 68 did not receive induction. Differences of efficacy and prognosis were assessed between the three groups.Hematologic overall response rates were 92% for the bortezomib group, 67% for the chemotherapy group, and 75% for the non-induction group, with complete response rates of 50%, 25%, and 20%, respectively. The renal response rates of the bortezomib, chemotherapy, and non-induction groups were 64%, 46%, and 47%, respectively, and cardiac response rates were 74%, 45%, and 40%, respectively.Median overall survival (OS) was not met at 44 months. The five-year estimated OS of the three groups was 81% for bortezomib, 57% for chemotherapy, and 67% for non-induction. Median progression-free survival (PFS) was 83 months for all patient groups. The five-year estimated PFS rates were 61% for bortezomib, 38% for chemotherapy, and 49% for non-induction.Upon multivariate analysis, a baseline difference between involved and uninvolved free light chains of more than 50 mg/L was associated with worse survival. Overall, induction with bortezomib was associated with better survival.This <a href="https://pubmed.ncbi.nlm.nih.gov/33084412/">study</a> was published in Amyloid.

Leah Lawrence

Asthma Risk Greater in Female Night Shift Workers

Asthma

Lauren Dembeck, PhD

Multi-Strain Probiotic Well Tolerated by Patients With IBD and IBS Symptoms

Gastroenterology

Comorbidities and Systemic Steroid Use Drive Pneumonia Risk in Patients With IBD

Latest News

Bortezomib-Based Induction Before AHCT Is Beneficial For Low Disease Burden AL Amyloidosis

Oncology

Patients with light-chain (AL) amyloidosis with low disease burden who are eligible for autologous hematopoietic cell transplantation (AHCT) may benefit from receiving ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Diabetes

Obesity

Metabolic Care Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe